More than one-third of reproductive-aged women enrolled in Medicaid, and more than a quarter of those with private insurance, filled a prescription for an opioid pain medication each year during 2008 to 2012, according to a recent report in Morbidity and Mortality Weekly Report (MMWR).
FDA approved lisdexamfetamine dimesylate (Vyvanse, Shire) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (BED) in adults, shown to significantly reduce the mean number of binge days per week.
Statin treatment reduces the risk of cardiovascular disease in women, according to a large international study, published in The Lancet.
Hydrocodone bitartrate (Hysingla ER, Purdue Pharma) extended-release tablets CII is now commercially available.
FDA has approved the antiretroviral Prezcobix (darunavir 800 mg/cobicistat 150 mg, Janssen Therapeutics) for the treatment of human immunodeficiency virus 1 (HIV-1).
FDA has approved expanded use of ibrutinib for the treatment of Waldenstroms Macroglobulinemia.
To save money, almost 8% of U.S. adults did not take their medication as prescribed, according to National Center for Health Statistics report.
FDA's process for approving drugs and devices is speeding up, according to a PricewaterhouseCoopers (PwC) Health Research Institute report.
Patients perceptions of drug cost may affect how they benefit from the drug, even when receiving a placebo.
Indiana will become the 28th state, plus the District of Columbia, to expand Medicaid under the Affordable Care Act (ACA).
A large study links a significantly increased risk for developing dementia, including Alzheimers disease, to taking commonly used medications with anticholinergic effects at higher doses or for a longer time, according to a study published in JAMA Internal Medicine. Many older people take these medications, which include nonprescription diphenhydramine (Benadryl).
Measurable goals and a timeline to move the Medicare program towards a value versus volume reimbursement model is being called a "transformative shift" that could redefine how care should be provided, measured and rewarded.
FDA approved ferric pyrophosphate citrate (Triferic, Rockwell Medical Inc.) for commercial sale as an iron replacement product to maintain hemoglobin in adult patients with hemodialysis dependent chronic kidney disease.
FDA approved the first generic version of Nexium (esomeprazole magnesium delayed-release capsules, Ivax Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceuticals USA) to treat gastroesophageal reflux disease (GERD) in adults and children aged 1 year and older. Esomeprazole is a proton pump inhibitor that reduces the amount of acid in the stomach.
FDA has approved parathyroid hormone (Natpara, NPS Pharma) once-daily injection to control hypocalcemia in patients with hypoparathyroidism.
Celiac disease occurs due to a genetic intolerance to dietary ingested gluten peptides. This initiates an immune response, predominantly in the small bowel, that results in malabsorption and associated symptoms including chronic diarrhea with weight loss, steatorrhea, postprandial abdominal pain, and bloating.
Approximately one-third of patients on a novel oral anticoagulant (NOAC) received inappropriate dosing based on indication, renal function, or concomitant interacting medications during hospitalization in the intensive care unit, typically for stroke prevention in atrial fibrillation, according to data presented at the Society of Critical Care Medicine meeting in Phoenix.
It is important to ensure established migraine medications are available for the patients who need them, according to a new study published in the January issue of Headache.
FDA has approved secukinumab (Cosentyx, Novartis) for the treatment of moderate-to-severe plaque psoriasis.
Many studies have shown that nonadherence to medications is associated with numerous adverse outcomes (including hospitalizations, higher costs, and increased mortality).
Consumer-driven healthcare has transformed from media buzzword to meaningful action, but it’s the economics behind the healthcare universe that have finally turned the consumer-driven concept into a reality for benefits administrators, employers and consumers alike.
FDA and the Centers for Disease Control and Prevention (CDC) continue to investigate multiple instances of Wallcur’s simulated intravenous (IV) saline products being administered to patients. These products are not sterile and should not be injected in humans or animals.
Healthcare providers need to help patients understand how alcohol can interact with their medications, according to a study from the National Institutes of Health and published in the February 2015 issue of Alcoholism: Clinical and Experimental Research.
FDA approved Phoxillum Renal Replacement Solutions.
According to the research firm Gartner, Inc., information technology is subject to a five-phase acceptance cycle: a Technology Trigger, Peak of Inflated Expectations, Trough of Disillusionment, Slope of Enlightenment, and Plateau of Productivity. Even zealous advocates of social media marketing (SMM) admit their craft is currently stuck in the disillusionment phase.
Since Virginia became the first state in May 2013 to enact legislation regulating a pharmacist’s substitution of an interchangeable biologic drug for a prescribed reference biologic drug, there has not been much activity or clarity on the issue.
With the launch of two open enrollment cycles behind it, the U.S. Department of Health and Human Services has turned its attention to promoting HealthCare.gov with a growing list of partners.
In the healthcare industry, most executives have placed huge caveats on their organization's plans for 2015. Looming this year are three potential game changers: the United States Supreme Court's King v. Burwell decision, a new Republican-controlled Senate's actions on the Affordable Care Act (ACA) and the implementation of ICD-10.
While ICD-10 implementation has been delayed until October 2015, providers must appreciate that many current managed care agreements likely include binding language that will impact reimbursement changes, particularly for inpatient services.
